For the quarter ending 2026-03-31, DOC had $728,207K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 199,656 | 121,792 | -109,848 | 39,019 |
| Depreciation and amortization of real estate, in-place lease, and other intangibles | 289,734 | 262,086 | 262,317 | 265,916 |
| Stock-based compensation amortization expense | 4,502 | 4,000 | 4,045 | 1,738 |
| Merger-related post-combination stock compensation expense | - | 0 | 0 | 0 |
| Stock-based compensation issued as part of initial public offering of janus living, inc | 4,872 | - | - | - |
| Amortization of deferred financing costs and debt discounts (premiums) | 8,363 | 8,199 | 7,981 | 7,875 |
| Straight-line rents | 10,905 | 8,354 | 14,282 | 5,401 |
| Amortization of above (below) market lease intangibles | -6,597 | -36,747 | - | - |
| Amortization of non-refundable entrance fees and above (below) market lease intangibles | - | - | -32,261 | -33,736 |
| Amortization of non-refundable entrance fees | -27,203 | -98,912 | - | - |
| Equity loss (income) from unconsolidated joint ventures | 4,265 | 2,707 | -176,291 | 1,747 |
| Distributions of earnings from unconsolidated joint ventures | 251 | 256 | 7,141 | 2,626 |
| Deferred income tax expense (benefit) | -1,086 | 3,976 | -2,199 | 1,122 |
| Impairments and loan loss reserves (recoveries), net | -2,275 | -776 | -54 | 3,499 |
| Loss (gain) on debt extinguishments | -403 | - | - | - |
| Loss (gain) on sales of real estate, net | 50,669 | 56,352 | 11,500 | 1,636 |
| Loss (gain) upon change of control, net | 138,117 | 0 | 0 | 0 |
| Casualty-related loss (recoveries), net | 190 | 9,204 | 1,483 | -5,059 |
| Other non-cash items | 2,739 | 2,506 | 2,612 | 2,556 |
| Decrease (increase) in accounts receivable and other assets | -890 | 26,023 | 21,127 | -23,671 |
| Increase (decrease) in accounts payable, accrued liabilities, and other liabilities | -40,706 | -112,156 | 52,552 | 58,036 |
| Increase (decrease) in deferred revenue | 36,962 | 147,297 | - | - |
| Net cash provided by (used in) operating activities | 260,881 | 294,084 | 314,961 | 363,485 |
| Acquisitions of real estate | 427,849 | 442,823 | 6,347 | 0 |
| Joint venture buyout, net | 291,354 | - | - | - |
| Development, redevelopment, and other major improvements of real estate | 142,132 | 216,569 | 222,715 | 158,332 |
| Leasing costs, tenant improvements, and recurring capital expenditures | 23,956 | 57,826 | 27,261 | 25,728 |
| Proceeds from sales of real estate, net | 90,359 | 306,885 | 25,750 | 5,089 |
| Proceeds from the callan ridge jv transaction, net | - | - | 0 | 0 |
| Proceeds from the bx jv i and ii transaction, net | 162,801 | 0 | - | - |
| Investments in unconsolidated joint ventures | 1,171 | 10,444 | 22,422 | 21,473 |
| Distributions in excess of earnings from unconsolidated joint ventures | 8,873 | 5,758 | 7,197 | 8,070 |
| Proceeds from insurance recovery | 6,838 | 7,829 | 10,538 | 1,290 |
| Proceeds from sales/principal repayments on loans receivable and other | 5,040 | 22,368 | 58,640 | 3,146 |
| Investments in loans receivable and other | 26,056 | 20,798 | 11,460 | 22,321 |
| Cash paid in connection with the merger, net | - | 0 | 0 | 0 |
| Net cash provided by (used in) investing activities | -638,607 | -405,620 | -188,080 | -210,259 |
| Borrowings under bank line of credit and commercial paper | 5,887,650 | 2,685,420 | 2,702,000 | 2,454,650 |
| Repayments under bank line of credit and commercial paper | 5,215,091 | 1,974,695 | 3,108,875 | 1,843,650 |
| Issuances and borrowings of term loans, senior unsecured notes, and mortgage debt | 0 | 0 | 492,765 | 0 |
| Repayments and repurchases of term loans, senior unsecured notes, and mortgage debt | 102,231 | 940 | 916 | 452,712 |
| Payments for debt extinguishment and deferred financing costs | 3,738 | 126 | 1,133 | 0 |
| Issuance of common stock, net of offering costs | 97 | 842 | 133 | 107 |
| Repurchase of common stock | 1,374 | 87 | 17 | 72,082 |
| Dividends paid on common stock | 211,994 | 211,861 | 211,874 | 211,881 |
| Distributions to and redemption of noncontrolling interests | 141,749 | 9,047 | 9,665 | 8,955 |
| Proceeds from janus living initial public offering, net of underwriting fees | 901,326 | 0 | 7,154 | 5,970 |
| Noncontrolling interest issuance costs | 6,963 | - | - | - |
| Net cash provided by (used in) financing activities | 1,105,933 | 489,506 | -130,428 | -128,553 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 728,207 | 377,970 | -3,547 | 24,673 |
| Cash, cash equivalents, and restricted cash, beginning of period | 537,702 | 159,732 | 163,279 | 138,606 |
| Cash, cash equivalents, and restricted cash, end of period | 1,265,909 | 537,702 | 159,732 | 163,279 |
HEALTHPEAK PROPERTIES, INC. (DOC)
HEALTHPEAK PROPERTIES, INC. (DOC)